Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MedImmune to license Siga its pillus technology

Executive Summary

Siga has signed a letter of intent with MedImmune whereby it will gain exclusive rights to MedImmune's gram negative antibiotic targets, product screens and services. In exchange for these rights, MedImmune will receive 335,530 shares of Siga stock.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies